BioWorld

Feb. 21, 2002

View Archived Issues

IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma

IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today) Read More

Fresh From Mergers, Buyouts, CEOs Mull Boons And Pitfalls

Read More

Pseudomonas aeruginosa, Lethal Cystic Fibrosis Scourge, Trades Surprise Blows With Scientists

Read More

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Read More

Other News To Note

Read More

Bush Might Have Final Say On Biotech’s Role In Bioterrorism

Read More

Anadys, Structural GenomiX Form Antibacterials Alliance

Read More